Liquidia Technologies to Present at Jefferies London Healthcare Conference

world news, trump, u.s., business news, stock market, entertainment news, business news, company news, market, commodities, commodity, Africa news

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2018 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the Jefferies London Healthcare Conference on Thursday, November 15, 2018 at 12:40 p.m. GMT (7:40 a.m. ET).

A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the company’s corporate website, and will be archived for a minimum of 90 days.

About Liquidia Technologies

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT® particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Being evaluated in a Phase 3 clinical trial (INSPIRE), LIQ861 is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, disposable dry powder inhaler. LIQ865, for which Liquidia has completed a U.S. Phase 1b clinical trial, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration. In addition to developing its own product candidates, Liquidia collaborates with leading pharmaceutical companies to develop their own product candidates across a wide range of therapeutic areas, molecule types and routes of administration, leveraging Liquidia’s PRINT® technology. For more information visit our website at www.liquidia.com.

Contact:
Jennifer Almond
Director, Investor Relations & Corporate Communications
919.328.4389
[email protected]

LIQUIDIA_Logo.jpg

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection there with. If you are affiliated with this page and would like it removed please contact [email protected]

Advertisements